Literature DB >> 7059442

Antihypertensive effects of lofexidine in patients with essential hypertension.

T C Fagan, S S Bloomfield, T D Cowart, R H Corns-Hurwitz, R J Lipicky, E C Conradi, C Y Hsu, W J Grossman, G E Harmon, W J Degenhart, A W Sinkfield, T E Gaffney.   

Abstract

1 Single oral doses of lofexidine, 0.1, 0.3, and 0.6 mg produced dose related decreases in supine and standing arterial pressure and heart rate in nineteen patients with essential hypertension. 2 A mean oral antihypertensive threshold dose of less than 0.1 mg was estimated. 3 Lofexidine decreased mean urinary noradrenaline excretion 28% and caused significant retention of sodium and water. 4 The most prominent side effects were sedation and orthostatic dizziness. 5 Lofexidine is pharmacologically similar to, but apparently less potent than clonidine as an antihypertensive agent.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7059442      PMCID： PMC1402104          DOI： 10.1111/j.1365-2125.1982.tb01393.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  10 in total

1.  THE DISTRIBUTION OF DOPAMINE AND DOPA IN VARIOUS ANIMALS AND A METHOD FOR THEIR DETERMINATION IN DIVERSE BIOLOGICAL MATERIAL.

Authors:  A H ANTON; D F SAYRE
Journal:  J Pharmacol Exp Ther       Date:  1964-09       Impact factor: 4.030

2.  A study of the factors affecting the aluminum oxide-trihydroxyindole procedure for the analysis of catecholamines.

Authors:  A H ANTON; D F SAYRE
Journal:  J Pharmacol Exp Ther       Date:  1962-12       Impact factor: 4.030

3.  Effects of clonidine on biochemical indices of sympathetic function and plasma renin activity in normotensive man.

Authors:  L M Wing; J L Reid; C A Hamilton; P Sever; D S Davies; C T Dollery
Journal:  Clin Sci Mol Med       Date:  1977-07

4.  Pharmacokinetics and concentration-effect relationships of intervenous and oral clonidine.

Authors:  D S Davies; A M Wing; J L Reid; D M Neill; P Tippett; C T Dollery
Journal:  Clin Pharmacol Ther       Date:  1977-05       Impact factor: 6.875

5.  Pharmacodynamic effects of a new antihypertensive drug, Catapres (ST-155).

Authors:  G Onesti; A B Schwartz; K E Kim; C Swartz; A N Brest
Journal:  Circulation       Date:  1969-02       Impact factor: 29.690

6.  Studies on catecholamines, renin and aldosterone following Catapresan (2-(2,6-dichlor-phenylamine)-2-imidazoline hydrochloride) in hypertensive patients.

Authors:  B Hökfelt; H Hedeland; J F Dymling
Journal:  Eur J Pharmacol       Date:  1970       Impact factor: 4.432

7.  Clinical observations on a new antihypertensive drug, 2-(2,6-dichlorphenylamine)-2-imidazoline hydrochloride.

Authors:  G Smet; S W Hoobler; S Sanbar; S Julis
Journal:  Am Heart J       Date:  1969-04       Impact factor: 4.749

8.  The effects of alpha adrenergic agents on human platelet aggregation.

Authors:  C Y Hsu; D R Knapp; P V Halushka
Journal:  J Pharmacol Exp Ther       Date:  1979-03       Impact factor: 4.030

9.  Pharmacokinetic and concentration-effect relationships of clonidine in essential hypertension.

Authors:  L M Wing; J L Reid; D S Davies; E A Neill; P Tippett; C T Dollery
Journal:  Eur J Clin Pharmacol       Date:  1977-12-28       Impact factor: 2.953

10.  Pharmacokinetics of clonidine and its relation to the hypotensive effect in patients.

Authors:  M Frisk-Holmberg; P O Edlund; L Paalzow
Journal:  Br J Clin Pharmacol       Date:  1978-09       Impact factor: 4.335
  10 in total
  1 in total

Review 1.  A Comprehensive Update of Lofexidine for the Management of Opioid Withdrawal Symptoms.

Authors:  Ivan Urits; Anjana Patel; Robbie Zusman; Celina Guadalupe Virgen; Mohammad Mousa; Amnon A Berger; Hisham Kassem; Jai Won Jung; Jamal Hasoon; Alan D Kaye; Omar Viswanath
Journal:  Psychopharmacol Bull       Date:  2020-07-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.